Mumbai, Maharashtra, India, December 2025 – Parul Sood has joined Servier India as Marketing Director, taking charge of the company’s Cardio Metabolic & Venous Diseases (CMVD) business. In this pivotal leadership role, she will lead marketing and digital strategy initiatives, spearhead strategic growth efforts, and focus on deepening scientific engagement and clinician partnerships across India and global markets.
In her words, Parul shared, “Servier’s deep commitment to innovation, science, people, and long-term value creation strongly resonate with me. I’m looking forward to driving strategic growth, strengthening scientific engagement & clinician partnerships, and contributing to advancing CMVD care alongside the exceptional teams in India & globally!”
Before joining Servier, Parul Sood spent over eight years at Zydus Group, where she most recently served as General Manager – Sales & Marketing, leading the BioNext division as P&L Head. Prior to that, as Deputy General Manager, she led the marketing for the Gastroenterology and Hepatology portfolio and headed sales for East and West zones.
Her earlier stint at Zydus included serving as Head of Marketing – NASH & IBD, where she launched groundbreaking therapies like BILYPSA, the first drug approved globally for NASH/NAFLD, and Exemptia, India’s first biosimilar of Adalimumab. She also conceptualized national and global physician engagement and therapy awareness initiatives.
Prior to Zydus, Parul spent over six years at Gland Pharma Limited, holding roles including Assistant General Manager – Marketing & Business Development and Senior Manager – Strategic Marketing, leading strategic marketing, new product development, and sales initiatives in the domestic market.
She began her career at Ind-Swift Limited as a Product Executive and was active in youth-led social initiatives during her time as Joint Head – Chandigarh Operations at Youth United, an NGO.
About Servier
Servier is a global pharmaceutical group governed by a non-profit foundation. With a history of over 70 years, the group is committed to therapeutic innovation and long-term social impact for patients. Servier is a world leader in cardiometabolism and venous diseases, while also making significant strategic shifts into oncology and neurology. With over 22,000 employees worldwide, Servier’s medicines are available in nearly 140 countries. In FY 2023–24, the group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion, reflecting its strong growth and sustainability focus.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
